Plasma visfatin and retinol binding protein-4 levels in patients with type 2 diabetes mellitus and their relationship to adiposity and fatty liver

Clinical Biochemistry

Volumn 44, Issue 17-18, 2011, Pages 1457-1463

  Shaker, Olfat ^a   El Shehaby, Amal ^a   Zakaria, Abir ^a   Mostafa, Naglaa ^a   Talaat, Soha ^a   Katsiki, Niki ^b   Mikhailidis, Dimitri P ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Insulin resistance; Liver fat; Obesity; Retinol binding protein 4; Subcutaneous fat; Type 2 diabetes mellitus; Visfatin

Indexed keywords

CHOLESTEROL; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RETINOL BINDING PROTEIN 4; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE DURATION; FATTY LIVER; FEMALE; HEMOGLOBIN BLOOD LEVEL; HOMEOSTATIC MODEL ASSESSMENT INSULIN RESISTANCE; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIVER FATTY DEGENERATION; MALE; MEDICAL PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SUBCUTANEOUS FAT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO;

ADIPOSITY; BIOLOGICAL MARKERS; BLOOD PRESSURE; BODY MASS INDEX; CASE-CONTROL STUDIES; CYTOKINES; DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; REGRESSION ANALYSIS; RETINOL-BINDING PROTEINS, PLASMA; SUBCUTANEOUS FAT;

EID: 81555205817     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.08.1148     Document Type: Article

References (52)

1. Kahn B.B., Flier J.S. Obesity and insulin resistance. J Clin Invest 2000, 106:473-481.
2. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89(6):2548-2556.
3. Athyros V.G., Tziomalos K., Karagiannis A., et al. Should adipokines be considered in the choice of the treatment of obesity-related health problems?. Curr Drug Targets 2010, 11(1):122-135.
4. Fox C.S., Massaro J.M., Hoffmann U., et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007, 116(1):39-48.
5. Thörne A., Lönnqvist F., Apelman J., et al. A pilot study of long term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. Int J Obes Relat Metab Disord 2002, 26(2):193-199.
6. Fain J.N., Madan A.K., Hiler M.L., et al. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004, 145(5):2273-2282.
7. Filippatos T., Randeva H., Derdemezis C., et al. Visfatin/PBEF and atherosclerosis-related diseases. Curr Vasc Pharmacol 2010, 8(1):12-28.
8. Fukuhara A., Matsuda M., Nishizawa M., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005, 307(5708):426-430.
9. Samal B., Sun Y., Stearns G., et al. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Molec Cell Biol 1994, 14(2):1431-1437.
10. Kralisch S., Klein J., Lossner U., et al. Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. J Endocrinol 2005, 185(3):R1-R8.
11. Choi K., Ryu O., Lee K., et al. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochem Biophys Res Comm 2005, 336(3):747-753.
12. Berndt J., Klting N., Kralisch S., et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005, 54(10):2911-2916.
13. Chen M., Chung F., Chang D., et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006, 91(1):295-299.
14. Graham T., Yang Q., Bluher M., et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006, 354(24):2552-2563.
15. Yang Q., Graham T., Mody N., et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005, 436(7049):356-362.
16. Gavi S., Stuart L., Kelly P., et al. Retinol-binding protein 4 is associated with insulin resistance and body fat distribution in non-obese subjects without type 2 diabetes. J Clin Endocrinol Metab 2007, 92(5):1886-1890.
17. Stefan N., Hennige A., Staiger H., et al. High circulating retinol binding protein 4 is associated with elevated liver fat, but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care 2007, 30(5):1173-1178.
18. Van der Kooy K., Seidell J.C. Techniques for the measurement of visceral fat: a practical guide. Int J Obes Relat Metab Disord 1993, 17:187-196.
19. Snijder M., Visser M., Dekker J., et al. The prediction of visceral fat by dual- energy X-ray absorptiometry in the elderly: a comparison with computed tomography and anthropometry. Int J Obes Relat Metab Disord 2002, 26(7):984-993.
20. Cnop M., Landchild M., Vidal J. The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentration: distinct metabolic effects of 2 fat compartments. Diabetes 2002, 51(4):1005-1015.
21. Dixon A.K. Abdominal fat assessed by computed tomography: sex difference in distribution. Clin Radiol 1983, 34(2):189-191.
22. Owens S., Gutin B., Ferguson M., et al. Visceral adipose tissue and cardiovascular risk factors in obese children. J Pediatr 1998, 133(1):41-45.
23. Leite C.C., Wajchenberg B.L., Radominski R., et al. Intra-abdominal thickness by ultrasonography to predict risk factors for cardiovascular disease and its correlation with anthropometric measurements. Metabolism 1992, 51(8):1034-1040.
24. Hirooka M., Kumagi T., Kurose K. A technique for the measurement of visceral fat by ultrasonography: comparison of measurements by ultrasonography and computed tomography. Intern Med 2005, 44(8):794-799.
25. World health organization Obesity: preventing and managing the global epidemic, Geneva 1998.
26. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2005, 28(1):S37-S42.
27. Danilova L.A., Lopatina N.I. Colorimetric method of determining glycosylated haemoglobin. Laboratórne Delo 1986, 5:281-283.
28. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28(7):412-419.
29. McTernan C.L., McTernan P.G., Harte A.L., et al. Resistin, central obesity, and type 2 diabetes. Lancet 2002, 359(9300):46-47.
30. Jia S.H., Li Y., Parodo J., et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004, 113(9):1318-1327.
31. Rongvaux A., Sea R.J., Mulks M.H., et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphor ribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 2002, 32(11):3225-3234.
32. Kitani T., Okuno S., Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor. FEBS Lett 2003, 544(1-3):74-78.
33. Hug C., Lodish H.F. Visfatin: a new adipokine. Science 2005, 307(5708):366-367.
34. +-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circ Res 2005, 97(1):25-34.
35. Arner P. Visfatin: a true or false trail to type 2 diabetes mellitus. J Clin Endocrinol Metab 2006, 91(1):28-30.
36. Haider D.G., Schaller G., Kapiotis S., et al. The release of the adipokine visfatin is regulated by glucose and insulin. Diabetologia 2006, 49(8):1909-1914.
37. Pagano C., Pilon C., Olivieri M., et al. Reduced plasma visfatin/pre-B cell colony enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006, 91(8):3165-3170.
38. Haider D.G., Schindler K., Schaller, et al. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006, 91(4):1578-1581.
39. Stadler M., Storka A., Theuer E.A., et al. Adipokines in type 1 diabetes after successful pancreas transplantation: normal visfatin and retinol-binding-protein-4, but increased total adiponectin fasting concentrations. Clin Endocrinol 2010, 72(6):763-769.
40. Hammarstedt A., Pihlajamäki J., Sopasakis V.R., et al. Visfatin is an adipokine, but it is not regulated by thiazolidinediones. J Clin Endocrinol Metab 2006, 91(3):1181-1184.
41. CLin C., Lai M.M., Li T.C., et al. Relationship between serum retinol-binding protein 4 and visfatin and the metabolic syndrome. Diabetes Res Clin Pract 2009, 85(1):24-29.
42. Cho Y.M., Youn B.S., Lee H., et al. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 2006, 29(11):2457-2461.
43. Janke J., Engeli S., Boschmann M., et al. Retinol-binding protein 4 in human obesity. Diabetes 2006, 55(10):2805-2810.
44. Lewis J.G., Shand B.I., Frampton C.M., et al. Plasma retinol binding protein is not a marker of insulin resistance in overweight subjects: a three year longitudinal study. Clin Biochem 2008, 41(13):1034-1038.
45. Meigs J.B., Panhuysen C.I., Myers R.H., et al. A genome-wide scan for loci linked to plasma levels of glucose and HbA1c in a community-based sample of Caucasian pedigrees: the Framingham Offspring Study. Diabetes 2002, 51(3):833-840.
46. Schindler K., Haider D., Wolzt M., et al. Impact of antiretroviral therapy on visfatin and retinol binding protein 4 in HIV-infected subjects. Eur J Clin Invest 2006, 36(9):640-646.
47. Matsuzawa Y. The metabolic syndrome and adipokines. FEBS Lett 2006, 580(12):2917-2921.
48. Blaner W.S. Retinol-binding protein: the serum transport protein for vitamin A. Endocr Rev 1989, 10(3):308-316.
49. Yki-Järvinen H., Westerbacka J. The fatty liver and insulin resistance. Curr Molec Med 2005, 5(3):287-295.
50. Roden M. Mechanisms of disease: hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance. Natl Clin Prac Endocrinol Metab 2006, 2(6):335-338.
51. Petersen K.F., Dufour S., Befroy D., et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005, 54(3):603-608.
52. Samuel V.T., Liu Z.X., Qu X., et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004, 279(31):32345-32353.